Page-TitleABOUT

REINVENTING HOW HEALTHCARE PROFESSIONALS AND PATIENTS MANAGE PAIN

Pain is a universal condition, while the perception of pain is unique. Virpax Pharmaceuticals is committed to developing non-addictive product candidates that manage pain and its complexities, while providing treatment options and minimizing risks to patients and society. By combining selected drug compounds with our cuttingedge delivery systems, we strive to maximize our products’ capabilities and successfully bring them to market. We believe our proprietary delivery systems will reinvent how patients and prescribers manage pain worldwide.

NON-ADDICTIVE PRODUCTS

We are advancing drug development strategies that will address the prominent need for nonaddictive alternatives in treatment of pain and CNS disorders. Our Molecular Envelope Technology (MET), topical spray film technology, and liposomal hydrogel technology will significantly improve our drug delivery characteristics by directly targeting pain symptoms and CNS Disorder symptoms at their source.

CNS GROWTH OPPORTUNITIES

Our MET platform is being used to grow our Central Nervous System (CNS) disorder pipeline. These additional patented formulations may include neurotransmission and neuroprotective actives. The current product candidates include Post Traumatic Stress Disorder (PTSD), and Rare Pediatric Epilepsy. In the future, the MET will be used to deliver actives that will be developed to manage other neurodegenerative disorders.

CalloutTRANSFORMINGDRUG-DELIVERYTECHNOLOGIES
Learn more

“Biopharma companies have a deep understanding of the R&D of novel products, making the industry essential to the advancement of public health initiatives.”

ANTHONY P. MACK
CEO of Virpax Pharmaceuticals

Prescribers, regulators, and patients are seeking non-addictive treatment options to combat the opioid epidemic.

The FDA is fostering the development of non-addictive alternatives to opioids for acute pain management.
SubheadAREAS OF FOCUS

We are continuously strengthening our worldwide patents in the development of non-addictive treatments for pain and degenerative neurological disorders.

We are seeking FDA approval for a robust pipeline of product candidates that will radically change how clinicians prescribe pain and CNS disorder therapies in the future.

BRINGING THE BEST MINDS TOGETHER

Our team has over 100 years of combined executive experience in the pharmaceutical industry and extensive knowledge in developing and commercializing pharmaceutical products.

Learn more

DISCOVER THE BENEFITS OF OUR LATEST TECHNOLOGY ADVANCEMENTS

LEARN MORE

DISCOVER THE BENEFITS OF OUR LATEST TECHNOLOGY ADVANCEMENTS

LEARN MORE